Results 161 to 170 of about 24,071 (243)

Trends in Anti-Vascular Endothelial Growth Factor Injections Among Medicare Part B Beneficiaries in 2013-2021 and the Step Therapy Era. [PDF]

J Vitreoretin Dis
Bryan JM, Sheth N, Heiferman MJ.
europepmc   +1 more source

Predictive factors for non-response to intravitreal aflibercept treatment in neovascular age-related macular degeneration

, 2016
Norihiro Nagai, Misa Suzuki, Atsuro Uchida, Toshihide Kurihara, Mamoru Kamoshita, Sakiko Minami, Hajime Shinoda, Kazuo Tsubota, Yoko Ozawa   +8 more
openalex   +1 more source

Comparative Real-World Efficacy of Anti-Vascular Endothelial Growth Factor Agents in Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Study.

Ophthalmologica
Berco E, Kozlov Y, Ostrovsky M, Tuli R, Kin Man Lee T, Samocha K, Shcolnik E, Goldfeather Ben Zaken S, Shoham-Hazon N.   +8 more
europepmc   +1 more source

Antibody-based therapeutics and therapeutic development for diabetic retinopathy: targeting VEGF, Ang/Tie, and inflammatory pathways. [PDF]

Front Endocrinol (Lausanne)
Zong Y, Qiu S, Zhang H, Wu J, Du J, Kamoi K, Cen Z.   +6 more
europepmc   +1 more source

Intravitreal faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration: short and long-term outcomes and assessment of volume dynamics using an artificial intelligence-based tool. [PDF]

Int J Retina Vitreous
Barbosa M, Bartolomeo N, Schuetz YP, Nascimbeni AC, Castro DG, Barry MP, Ambresin A.   +6 more
europepmc   +1 more source

Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study [PDF]

Andreas Stahl, Noriyuki Azuma, Wei‐Chi Wu, Domenico Lepore, Emine Alyamaç Sukgen, Hidehiko Nakanishi, Jan Mazela, Sergio Leal, Alexander Pieper, Sarah Schlief, Thomas Eißing, K. C. Turner, An Sha Zhao, Julia Winkler, Joachim Höchel, Evra Köfüncü, Torsten Zimmermann, on behalf of the FIREFLEYE Study Group   +17 more
openalex   +1 more source

Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration: XTEND at 3 Years [PDF]

Jean‐François Korobelnik, Varun Chaudhary, Paul Mitchell, Se Woong Kang, Helmut Allmeier, JinKyung Lee, Xin Zhang, Tobias Machewitz, Clare Bailey   +8 more
openalex   +1 more source

2018 Stuart Rome Lecture: Origins of and Potential Solutions to High Prescription Drug Prices in the U.S. [PDF]

, 2019
Kesselheim, Aaron S.
core   +1 more source

Intravitreal aflibercept (Eylea) injection for cystoid macular edema secondary to retinitis pigmentosa - a first case report and short review of the literature [PDF]

, 2015

core   +1 more source

Comparative outcomes of aflibercept biosimilars and reference aflibercept in nAMD: a systematic review and meta-analysis. [PDF]

BMJ Open Ophthalmol
Sawires K, Nithianandan H, Somani S.
europepmc   +1 more source